Your browser doesn't support javascript.
loading
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.
Bahleda, Rastislav; Italiano, Antoine; Hierro, Cinta; Mita, Alain; Cervantes, Andres; Chan, Nancy; Awad, Mark; Calvo, Emiliano; Moreno, Victor; Govindan, Ramaswamy; Spira, Alexander; Gonzalez, Martha; Zhong, Bob; Santiago-Walker, Ademi; Poggesi, Italo; Parekh, Trilok; Xie, Hong; Infante, Jeffrey; Tabernero, Josep.
Afiliação
  • Bahleda R; Gustave Roussy Cancer Campus and University Paris-Sud, Villejuif, France.
  • Italiano A; Institut Bergonie, Bordeaux, France.
  • Hierro C; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
  • Mita A; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
  • Cervantes A; Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
  • Chan N; Rutgers University, New Brunswick, New Jersey.
  • Awad M; Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Calvo E; START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain.
  • Moreno V; START Madrid-FJD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
  • Govindan R; Washington University School of Medicine, St. Louis, Missouri.
  • Spira A; Virginia Cancer Specialists Research Institute, Fairfax, Virginia; and US Oncology Research, The Woodlands, Texas.
  • Gonzalez M; Janssen Research & Development, Raritan, New Jersey.
  • Zhong B; Janssen Research & Development, Raritan, New Jersey.
  • Santiago-Walker A; Janssen Research & Development, Raritan, New Jersey.
  • Poggesi I; Janssen Research & Development, Raritan, New Jersey.
  • Parekh T; Janssen Research & Development, Raritan, New Jersey.
  • Xie H; Janssen Research & Development, Raritan, New Jersey.
  • Infante J; Janssen Research & Development, Raritan, New Jersey.
  • Tabernero J; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. jtabernero@vhio.net.
Clin Cancer Res ; 25(16): 4888-4897, 2019 08 15.
Article em En | MEDLINE | ID: mdl-31088831
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Quinoxalinas / Receptores de Fatores de Crescimento de Fibroblastos / Inibidores de Proteínas Quinases / Neoplasias / Antineoplásicos Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: França
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Quinoxalinas / Receptores de Fatores de Crescimento de Fibroblastos / Inibidores de Proteínas Quinases / Neoplasias / Antineoplásicos Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article País de afiliação: França